相关实验视频

Updated: Mar 3, 2026

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

血原缺乏症和阿波利波蛋白E4的阿尔茨海默病风险

Jenny Hällqvist¹, Jan-Willem Taanman², Andreas Göteson³

¹Translational Mass Spectrometry Research Group, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.

Brain communications

|March 2, 2026

概括

阿波利波蛋白E4 (APOE4) 异型与阿尔茨海默病的风险有关,原因是乙醇胺等离子素水平降低. 患有APOE4个体的这种脂质缺乏可能会导致疾病病理,提供潜在的治疗点.

科学领域:

神经科学是一个神经科学.
遗传学是一个遗传学.
生物化学生物化学

背景情况:

阿波利波蛋白E ε4 (APOE4) 基因是晚发性阿尔茨海默病 (AD) 的主要遗传风险因素.
APOE4增加AD风险的确切机制尚不清楚,提出了各种假设.
脂蛋白E在脂质运输和新陈代谢中的作用对于理解其功能和与AD的潜在联系至关重要.

研究的目的:

调查阿波利波蛋白E (apoE) 脂质关联性质是否依赖异型,并介导AD风险.
为了检查apoE异型与乙醇胺等离子原 (PL) 的相关性,乙醇胺等离子原是AD大脑中耗尽的脂.
为了确定与APOE4相关的PL缺陷是否先于神经退行.

主要方法:

使用免疫沉,从人类脑脊液 (CSF) 中净化apoE.
通过质谱学对纯化apoE-lipid复合物的脂质和蛋白质分析.
从已知APOE异型状态 (E3E3,E3E4,E4E4) 的认知完整个体采集的CSF样本的分析.

主要成果:

在E4E4个体中,与E3E3.3.4个体相比,观察到乙醇胺等离子体与apoE的摩尔比率显著降低.
发现了乙醇胺等离子素与apoE比率下降的生物梯度:E3E3 > E3E4 > E4E4.4.
在E3E4和E4E4个体中,乙醇胺等离子素与酸乙醇胺的比率显著降低,反映了AD大脑发现.

结论:

乙醇胺等离子素缺乏与APOE4相关,这表明AD风险增加的机制.
在APOE4载体中这种脂质消耗可能会导致AD的发病,而不是神经退行症的结果.
向乙醇胺等离子体水平可能代表阿尔茨海默病的治疗策略.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.亚脂蛋白 E 是一种非脂蛋白 E.乙醇胺等离子体生成物这种异形异形是什么?脂质组的类型是什么

更多相关视频

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...